(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 30 October 2003 (30.10.2003)

PCT

(10) International Publication Number WO 03/089002 A1

- (51) International Patent Classification⁷: A61K 45/00, 45/06, 38/04, 38/16, 39/395, A61P 15/00, A61K 9/00
- (21) International Application Number: PCT/GB03/01536
- (22) International Filing Date: 10 April 2003 (10.04.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0208785.6 0208783.1 17 April 2002 (17.04.2002) GB 17 April 2002 (17.04.2002) GB

- (71) Applicant (for all designated States except US): MEDI-CAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1B 1AL (GB).
- (72) Inventors; and
- (75) Inventors Applicants (for US only): JABBOUR, Henry, Nicolas [AU/GB]; MRC Human Reproductive Sciences


Unit, Centre for Reproductive Biology, The University of Edinburgh Academic Centre, 49 Little France Crescent, Old Dalkeith Road, Edinburgh EH16 4SB (GB). CRITCHLEY, Hilary, Octavia, Dawn [GB/GB]; Department of Obstetrics and Gynecology, University of Edinburgh, Centre for Reproductive Biology, Edinburgh EH3 9ET (GB).

- (74) Agent: MILES, John, S.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CII, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, IIR, IIU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: I'P RECEPTOR ANTAGONISTS OR PGF2 ALPIIA ANTAGONISTS FOR TREATING MENORRIIAGIA





(57) Abstract: A method of treating or preventing menorrhagia in an female individual the method comprising administering to the individual at least one agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor. Optionally, an inhibitor of PGES and/or an antagonist of EP2 or EP4 is also administered.